Analyst Price Targets — REGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 10:06 am | David Risinger | Leerink Partners | $824.00 | $803.48 | TheFly | Regeneron price target raised to $824 from $641 at Leerink |
| August 14, 2026 1:28 pm | Jeffrey Walch | Bernstein | $756.00 | $799.46 | StreetInsider | Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group |
| August 3, 2026 1:29 pm | — | Guggenheim | $1,030.00 | $763.51 | TheFly | Regeneron price target raised to $1,030 from $1,000 at Guggenheim |
| July 31, 2026 2:01 pm | — | RBC Capital | $737.00 | $739.50 | TheFly | Regeneron price target raised to $737 from $696 at RBC Capital |
| July 31, 2026 1:07 pm | — | Morgan Stanley | $758.00 | $738.82 | TheFly | Regeneron price target raised to $758 from $730 at Morgan Stanley |
| July 31, 2026 12:25 pm | Carter Gould | Cantor Fitzgerald | $795.00 | $742.59 | TheFly | Regeneron price target raised to $795 from $750 at Cantor Fitzgerald |
| July 31, 2026 11:22 am | — | Robert W. Baird | $761.00 | $738.34 | TheFly | Regeneron price target raised to $761 from $742 at Baird |
| July 31, 2026 10:17 am | — | Wells Fargo | $750.00 | $738.34 | TheFly | Regeneron price target raised to $750 from $700 at Wells Fargo |
| July 21, 2026 12:01 pm | Yatin Suneja | Guggenheim | $1,000.00 | $675.72 | TheFly | Regeneron price target raised to $1,000 from $995 at Guggenheim |
| July 9, 2026 11:13 am | Biren Amin | Piper Sandler | $854.00 | $662.88 | TheFly | Regeneron price target lowered to $854 from $855 at Piper Sandler |
Latest News for REGN
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) between August 1, 2025 and May 15, 2026, inclusive.
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN).
LOS ANGELES, Sept. 01, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Regeneron Pharmaceuticals, Inc., (“Regeneron” or the "Company") (NASDAQ: REGN) investors of a class action on behalf of investors that bought securities between August 1, 2025 and May 15, 2026, inclusive (the “Class Period”). Regeneron investors have until September 14, 2026 to file a lead plaintiff motion.
SAN FRANCISCO, Sept. 1, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma.
Time-Sensitive: Allegations focus on Regeneron's statements about clinical differentiation in the Phase III Fianlimab-Libtayo Study and the last-minute protocol amendment used to force a trial readout Time-Sensitive: Allegations focus on Regeneron's statements about clinical differentiation in the Phase III Fianlimab-Libtayo Study and the last-minute protocol amendment used to force a trial readout
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.